jRCT2051240133进行中（未招募）不适用
An Open-label Phase 3 Study of Setrusumab in Pediatric Japanese Subjects with Osteogenesis Imperfecta Type I, III, or IV
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 6
- 主要终点
- Annualized rate of all radiographically-confirmed fractures, including morphometric vertebral fractures
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Single Arm Study
- 干预模型
- Single Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 2age old over 至 7age old not（—）
- 性别
- All
入选标准
- •Male or female 2 to < 7 years of age at time of informed consent
- •Clinical diagnosis of OI Type I, III, or IV confirmed by identification of genetic mutation in COL1A1 or COL1A2
- •History of >= 1 fracture in the past 12 months,>= 2 fractures in the past 24 months, or >= 1 femur, tibia, or humerus fracture in the past 24 months
- •Any prior exposure to, or currently receiving, IV-bisphosphonate therapy for treatment of OI
- •Serum 25-hydroxyvitamin D level >= 20 ng/mL at the Screening visit. If 25-hydroxyvitamin D levels are below 20 ng/mL, the subject may be rescreened after a minimum of 14 days of vitamin D supplementation as directed by the Investigator
- •Must weigh >= 5 kg at Screening
排除标准
- •History of skeletal malignancies or bone metastases at any time
- •History of neural foraminal stenosis (except if due to scoliosis)
- •Clinical manifestations of Chiari malformation or basilar invagination. Presence of any other neurologic disease that has been clinically unstable within past 2 years requires review by the Medical Monitor.
- •History of or current uncontrolled concomitant diseases that may impact bone metabolism, such as hypo/hyperparathyroidism, abnormal thyroid function, nephrotic syndrome, or Stage IV/V renal disease
- •Any skeletal condition (other than OI) leading to bone deformity and/or increased risk of fractures, such as rickets, osteopetrosis, idiopathic juvenile osteoporosis, or skeletal dysplasia
- •History of known cardiovascular disease such as coronary artery anomaly, Kawasaki disease, myocarditis, cardiomyopathy, myocardial infarction, stroke, or thromboembolic disease. Individuals with other congenital or acquired cardiovascular disease necessitating an echocardiogram require Medical Monitor review. Investigators should consider whether the potential benefits of treatment outweigh the potential risks in patients with cardiovascular risk factors such as confirmed arterial hypertension.
- •Hypocalcemia, defined as serum calcium levels below the age-adjusted normal limit reference ranges after a recommended >= 4 hour fast, at Screening
- •Estimated glomerular filtration rate <= 35 mL/min/1.73 m2 at Screening
- •Prior treatment with growth hormone, denosumab, anti-sclerostin antibody, or other anabolic or anti-resorptive medications impacting the bone (other than bisphosphonates) at any time
- •History of external radiation therapy
- •Known hypersensitivity to setrusumab or its excipients that, in the judgment of the Investigator, places the subject at increased risk for adverse effects
- •Presence or history of any condition that, in the view of the Investigator, would interfere with participation, pose undue risk, or would confound interpretation of results
- •Use of any investigational product or investigational medical device within 4 weeks or 5 half-lives (whichever is longer) of investigational drug prior to Screening, or during the study (per discretion of the Investigator in consultation with the Medical Monitor)
- •Concurrent participation in another clinical study without prior approval from the study Medical Monitor
- •Pregnant or nursing
结局指标
主要结局
Annualized rate of all radiographically-confirmed fractures, including morphometric vertebral fractures
时间窗: Treatment Period
*Morphometric vertebral fracture identified by change from baseline in Genant semi-quantitative scoring based on annual spine radiographs
次要结局
- Annualized rate of radiographically-confirmed fractures, excluding morphometric vertebral fractures(Treatment Period)
- Change from baseline in dual-energy X-ray absorptiometry (DXA) BMD z-score at the lumbar spine(Treatment Period)
- Percent change from baseline in DXA BMD at the lumbar spine(Treatment Period)
- Serum setrusumab concentration(scheduled time points)
- Frequency, severity, and relationship to treatment of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events of special interest (AESIs)
- Incidence of binding and neutralizing anti-setrusumab antibodies(scheduled time points)
研究者
相似试验
进行中（未招募）
1 期
Ofatumumab versus Rituximab in treatment of children with steroid and calcineurin inhibitor-dependent idiopatic nephrotic syndrome:steroid and calcineurin inhibitor-dependent idiopatic nephrotic syndromeMedDRA version: 21.1Level: PTClassification code 10029164Term: Nephrotic syndromeSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2015-000624-28-ITIRCCS ISTITUTO GIANNINA GASLINI140
进行中（未招募）
1 期
Ofatumumab in children with nephrotic syndrome resistant to common therapySteroid- and calcineurin-inhibitor-resistant nephrotic syndromeMedDRA version: 21.0Level: LLTClassification code 10072914Term: Steroid-resistant nephrotic syndromeSystem Organ Class: 100000004857EUCTR2015-000569-30-ITIRCCS ISTITUTO GIANNINA GASLINI50
进行中（未招募）
2 期
Phase 2 study of JR-142 in pediatric patients with growth hormone deficiencyGrowth hormone deficiency in childrenJPRN-jRCT2031200372Ryo Ibaraki24
终止
不适用
Outcomes of patients with paediatric onset Inflammatory Bowel Disease (IBD) following transition into adult care –what do we know?Oral and Gastrointestinal - Inflammatory bowel diseaseInflammatory Bowel DiseaseACTRN12613000259741SA Department of Health200
招募中
3 期
Early rituximab treatment in children with idiopathic nephrotic syndrome Eng. ERICONS - Early RITUXIMAB in Childhood Onset Nephrotic Syndrome2024-515058-26-00Medical University Of Gdansk60